Corona-Swiss Ltd Accelerates Cancer Detection Test w/ Blockchain Along w/ Ryukyu Univ & Local Gov't

Early Cancer Detection Technique in approximately 10 minutes with 99% accuracy rate. Aiming to eliminate death caused by cancer in the future.

Corona-Swiss will conduct Cancer Test proof experiment to 1,500 people in Ie Village Okinawa. Featuring its 10 minutes result evaluation with 99% accuracy rate

The life of the individuals and their families can live with a peace of mind knowing there is an accurate early detection test with preventive medicine from BIOHAL.”
— Yuki Hasegawa

SLIEMA, MALTA , December 21, 2018 /EINPresswire.com/ -- Corona-Swiss Ltd., who is the owner of BIOHAL Network announced today that they will carry out a proof experiment by performing cancer risk screening for 1,500 Ie-islanders in Okinawa Prefecture. This cancer early detection test will start in June of 2019 and it will run for three years. This is with the cooperation of the University of Ryukyu, and the Local Government of Ie-Village. The official agreement was made on the 1st of November and the announcement was released last 30th of November.

Corona-Swiss, Ltd., aims to bridge the gap by giving the people access to its innovative solution and blockchain technique to store cancer data accurately as the medical cost for treatment has gone up, and not everyone can afford to foot the medical bills.

“The life of the individuals and their families can live with a peace of mind knowing there is an accurate early detection test with preventive medicine from BIOHAL.” Says Yuki Hasegawa, Founder/CEO, BIOHAL.

PROTEO®, a cancer risk screening test which is an epoch-making technique, that can evaluate the presence of any cancer in just 10 minutes. The procedure of PROTEO will continue until the risk test result of cancer goes out from a drop of blood. In comparison with other liquid biopsy tests, PROTEO features its 99% cancer accuracy test result rate. Also, the proteo liquid biopsy test can carry out to a pregnant woman and child safe because radiation is not used in this test.

Corona-Swiss Ltd., utilizes the data collected through PROTEO by using a blockchain (distributed ledger technology) technique and manages it. The Blockchain architecture is matched with a concept of patients’ data management of Corona-Swiss, and each patient can review the result of their screening test without any problem as well as check other DNA data as it is secured and made personal. The company will save know-how technique of the data technology for the next generation.

Corona-Swiss, Ltd
.
.
email us here


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.